1. Ireland Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Trinity Biotech plc

Trinity Biotech plc

TRIB
Trinity Biotech plcUS flagNASDAQ Global Select
0.34
USD
+0.00
- -
3.48MMarket Cap

Total Valuation

Trinity Biotech plc carries a market capitalization of 3.48M, placing it among publicly traded companies globally. Its enterprise value stands at 104.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.48M
Enterprise Value104.83M

Share Statistics

Trinity Biotech plc currently has 359.19M shares outstanding.

Shares Outstanding359.19M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 0.15, and the price-to-book ratio stands at -0.12.

PE RatioN/A
PS Ratio0.15
PB Ratio-0.12
P/TBV Ratio-0.11
P/FCF Ratio1.57
P/OCF Ratio-2.20

Enterprise Valuation

EV / Sales1.70
EV / EBITDAN/A
EV / EBITN/A
EV / FCF5.08

Financial Position

Trinity Biotech plc maintains a current ratio of 1.28, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -286.42, indicating conservative leverage, while an interest coverage ratio of -0.94 demonstrates limited ability to service its debt obligations.

Current Ratio1.28
Quick Ratio0.62
Debt / Equity-286.42
Debt / EBITDA-7.40
Interest Coverage-0.94

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-39.07
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.04

Taxes

Income Tax486,000.00
Effective Tax RateN/A

Stock Price Statistics

Trinity Biotech plc's stock has declined approximately -53.47222% over the past 52 weeks. The 50-day moving average sits at 0.54, while the 200-day moving average is 0.76.

Beta (5Y)N/A
52-Week Price Change-53.47222%
50-Day Moving Average0.54
200-Day Moving Average0.76
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Trinity Biotech plc generated 61.56M in revenue and converted that into -31.79M in net income, yielding earnings per share of -2.97. EBITDA reached -13.62M, while operating income came in at -15.49M.

Revenue61.56M
Gross Profit21.44M
Operating Income-15.49M
Pretax Income-30.73M
Net Income-31.79M
EBITDA-13.62M
EBIT-15.49M
Earnings Per Share (EPS)-2.97

Balance Sheet

Trinity Biotech plc holds 5.17M in cash and equivalents against 100.76M in total debt, resulting in a net debt position of 82.84M. Total book value stands at -74.93M, with working capital of 9.03M providing operational flexibility.

Cash & Cash Equivalents5.17M
Total Debt100.76M
Net Debt82.84M
Equity (Book Value)-74.93M
Book Value Per Share-7.14
Working Capital9.03M

Cash Flow

Trinity Biotech plc produced -4.19M in operating cash flow over the past twelve months. After subtracting -10.06M in capital expenditures, free cash flow totaled -14.26M - equivalent to -1.36 per share.

Operating Cash Flow-4.19M
Capital Expenditures-10.06M
Free Cash Flow-14.26M
FCF Per Share-1.36

Margins

Trinity Biotech plc operates with a gross margin of 34.83, reflecting its pricing power and cost economics. The operating margin of -25.17 and net profit margin of -51.64 provide insight into operational efficiency.

Gross Margin34.83
Operating Margin-25.17
Pretax Margin-49.92
Profit Margin-51.64
EBITDA Margin-22.13

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-311.94
FCF Yield63.58

Stock Splits

Trinity Biotech plc's most recent stock split took place on July 24, 2026 with a 30:1 split ratio.

Last Split Date7/24/2026
Split Ratio30:1

Scores

Trinity Biotech plc posts an Altman Z-Score of -1.68, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.68